益肾口服液延缓肺衰老的试验研究

A clinical trial on the effectiveness of the oral liquid of tonifying kidney against lung senescence

目的观察益肾口服液延缓肺衰老的作用。方法 62例受试者随机分为试验组31例和对照组31例,试验组予益肾口服液24周,对照组不接受益肾口服液干预。观察受试前后受试者的用力肺活量(forced vital capacity,FVC)、第一秒用力呼气容积(forced expiratory volume in one second,FEV1)、一秒率(forced expiratory volume in one second/forced vital capacity,FEV1/FVC)、最大呼气中期流量(maximal mid-expiratory flow curve,MMEF)、最大分钟通气量(maximal minute volume,MVV)及最高呼气流量(peak expiratory flow,PEF),比较受试前后肺功能的变化。结果试验组受试后FVC和MVV较治疗前升高,差异有统计学意义(P<0.05);对照组FVC、FEV1、MMEF、MVV及PEF受试后较治疗前下降,差异有统计学意义(P<0.01);两组治疗前后FVC、FEV1、MMEF、MVV及PEF差值比较,差异有统计学意义(P<0.05。结论益肾口服液对于增龄所导致的肺脏衰老可能具有延缓作用。

Objective To observe the clinical efficacy of oral liquid of tonifying kidney on delaying the syndrome of lung senescence.Methods According to paired randomization,62 patients were divided into the treatment group(n = 31),with the oral liquid of tonifying kidney,and the control group(n = 31) without any related drugs.FVC,FEV1,FEV1/FVC,MMEF,MVV and PEF before and after the treatment were measured and compared.Results FVC,MW in the treatment group increased significantly after treatment(P< 0.05),while decreased significantly after treatment(P < 0.01) in the control group.There was significant difference between before and after the treatment in both groups on FVC,FEV1,MMEF,MVV and PEF index(P< 0.05).Conclusion Oral liquid of tonifying kidney appears effective against the syndrome of lung senescence.